(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.42%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
-0.07% INR 698.60
Live Chart Being Loaded With Signals
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally...
Stats | |
---|---|
Tagesvolumen | 1.35M |
Durchschnittsvolumen | 930 984 |
Marktkapitalisierung | 279.56B |
EPS | INR0 ( 2024-04-25 ) |
Nächstes Ertragsdatum | ( INR1.270 ) 2024-07-24 |
Last Dividend | INR0.750 ( 2023-06-30 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 54.96 |
ATR14 | INR0.778 (0.11%) |
Volumen Korrelation
Syngene International Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Syngene International Korrelation - Währung/Rohstoff
Syngene International Finanzdaten
Annual | 2023 |
Umsatz: | INR34.89B |
Bruttogewinn: | INR12.44B (35.65 %) |
EPS: | INR12.71 |
FY | 2023 |
Umsatz: | INR34.89B |
Bruttogewinn: | INR12.44B (35.65 %) |
EPS: | INR12.71 |
FY | 2022 |
Umsatz: | INR31.93B |
Bruttogewinn: | INR23.33B (73.06 %) |
EPS: | INR11.59 |
FY | 2022 |
Umsatz: | INR25.07B |
Bruttogewinn: | INR17.58B (70.12 %) |
EPS: | INR9.94 |
Financial Reports:
No articles found.
Syngene International Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0.750 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.500 | 2016-03-17 |
Last Dividend | INR0.750 | 2023-06-30 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 6 | -- |
Total Paid Out | INR3.25 | -- |
Avg. Dividend % Per Year | 0.05% | -- |
Score | 2.87 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.38 | |
Div. Directional Score | 8.64 | -- |
Year | Amount | Yield |
---|---|---|
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0.500 | 0.16% |
2019 | INR0.500 | 0.18% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0.500 | 0.08% |
2023 | INR0.750 | 0.13% |
2024 | INR0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
MARKSANS.NS | Dividend Junior | 2023-06-07 | Annually | 11 | 0.40% | |
GRINDWELL.NS | Dividend Junior | 2023-08-03 | Annually | 18 | 0.77% | |
BALMLAWRIE.NS | Dividend Knight | 2023-09-20 | Annually | 23 | 3.62% | |
POONAWALLA.NS | Dividend Junior | 2023-07-18 | Sporadic | 21 | 0.21% | |
JTLIND.NS | Dividend Junior | 2023-08-04 | Insufficient data to determine frequency | 2 | 0.04% | |
DPABHUSHAN.NS | Dividend Junior | 2023-09-22 | Annually | 3 | 0.15% | |
ABBOTINDIA.NS | Dividend Junior | 2023-07-20 | Annually | 17 | 0.52% | |
SPIC.NS | Dividend Junior | 2023-09-20 | Annually | 3 | 0.70% | |
MPHASIS.NS | Dividend Knight | 2023-07-05 | Annually | 20 | 1.43% | |
HESTERBIO.NS | Dividend Junior | 2023-09-13 | Annually | 10 | 0.31% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.146 | 1.500 | 7.08 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0829 | 1.200 | 7.24 | 8.68 | [0 - 0.3] |
returnOnEquityTTM | 0.127 | 1.500 | 9.70 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.712 | 0.800 | 6.44 | 5.15 | [1 - 3] |
quickRatioTTM | 1.327 | 0.800 | 6.90 | 5.52 | [0.8 - 2.5] |
cashRatioTTM | 0.492 | 1.500 | 8.38 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0309 | -1.500 | 9.48 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 14.26 | 1.000 | 5.83 | 5.83 | [3 - 30] |
operatingCashFlowPerShareTTM | 20.51 | 2.00 | 3.16 | 6.33 | [0 - 30] |
freeCashFlowPerShareTTM | 20.51 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0446 | -1.500 | 9.82 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.636 | 1.000 | 2.73 | 2.73 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.193 | 1.000 | 8.14 | 8.14 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.32 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.567 | 0.800 | 9.55 | 7.64 | [0.5 - 2] |
Total Score | 11.90 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 54.82 | 1.000 | 4.56 | 0 | [1 - 100] |
returnOnEquityTTM | 0.127 | 2.50 | 9.80 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 20.51 | 2.00 | 3.16 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.107 | 1.500 | 7.32 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 20.51 | 2.00 | 3.16 | 6.33 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 6.63 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.235 | 1.000 | 6.62 | 0 | [0.1 - 0.5] |
Total Score | 5.38 |
Syngene International
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally. The company provides discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also offers exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, as well as acute, sub-chronic, and chronic toxicity studies; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, biometrics and clinical data management, regulatory, medical monitoring, pharmacovigilance, and medical writing services. Further, it offers other drug modalities, which include peptides, oligonucleotide synthesis, antibody drug conjugate, PROTACs, and CAR T-cell therapy services. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.